These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16749523)

  • 1. Cost-effective psoriasis treatment may demand creative coverage rules.
    Morrow T
    Manag Care; 2006 May; 15(5):61-3. PubMed ID: 16749523
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost of psoriasis.
    Crown WH
    Manag Care; 2003 May; 12(5 Suppl):10-3; discussion 20-1. PubMed ID: 18564553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The convergence of psoriasis treatment cost-effectiveness over time: "real world" considerations in economic modeling.
    Goldberg LD
    J Am Acad Dermatol; 2008 Jun; 58(6):1073-5. PubMed ID: 18485990
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
    Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
    J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managed care's perspective on treatment of plaque psoriasis.
    Sullivan TJ
    Manag Care; 2003 May; 12(5 Suppl):14-7; discussion 20-1. PubMed ID: 18564554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic considerations in psoriasis management.
    Radtke MA; Augustin M
    Clin Dermatol; 2008; 26(5):424-31. PubMed ID: 18755360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of psoriasis treatment.
    Galadari I; Rigel E; Lebwohl M
    J Eur Acad Dermatol Venereol; 2001 Jul; 15(4):290-1. PubMed ID: 11730031
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost analysis of psoriasis treatments.
    Giaquinta D
    Manag Care Interface; 2006 Jun; 19(6):37-8. PubMed ID: 16892659
    [No Abstract]   [Full Text] [Related]  

  • 10. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
    Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
    Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How much should a psoriatic spot cost?].
    Gjersvik PJ
    Tidsskr Nor Laegeforen; 2004 Jan; 124(1):14. PubMed ID: 14716384
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany.
    Augustin M; Radtke M; van Engen A; Ruedig C; Lapp C; Moehling U
    J Dtsch Dermatol Ges; 2009 Apr; 7(4):329-38. PubMed ID: 19243481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus guidelines for specialty pharmaceuticals: a best-practice approach for cost-effective management.
    Sullivan SD
    Am J Manag Care; 2004 Aug; 10(8 Suppl):S242-4; discussion 245-51. PubMed ID: 15460521
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone.
    Augustin M; Peeters P; Radtke M; Moehling U; Lapp C
    Dermatology; 2007; 215(3):219-28. PubMed ID: 17823519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental cost-effectiveness ratio analysis of biologic treatments for psoriasis at clinically significant evaluation time points.
    Puig L; López-Ferrer A; Vilarrasa E
    Actas Dermosifiliogr; 2014 Dec; 105(10):951-3. PubMed ID: 24836110
    [No Abstract]   [Full Text] [Related]  

  • 16. Back to the future: the managed care approach to rheumatoid arthritis.
    Sidorov J
    Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of psoriasis on health care costs and patient work loss.
    Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
    J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic insomnia treatment and Medicare Part D: implications for managed care organizations.
    Navarro R; Mitrzyk BM; Bramley TJ
    Am J Manag Care; 2007 Nov; 13(5 Suppl):S121-4. PubMed ID: 18041872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
    Jhaveri M; Seal B; Pollack M; Wertz D
    Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The annual cost of psoriasis.
    Arikian SR; Einarson TR
    J Am Acad Dermatol; 1994 Jun; 30(6):1047-8. PubMed ID: 8188881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.